Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

全球医疗保健公司诺华(Novartis AG, NYSE: ...

10月29日，诺华公布2024年第三季度（Q3）财报。新闻稿指出，该公司在Q3继续保持强劲势头，销售额增长10%，高于预期的7%增幅，将上调2024 财年全年指导目标。其中诺华中国业务收入10亿美元，增长18%，高于全球增长数据。

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

在日常生活中，关心自身健康的你是否曾听说过银屑病？这种常见的慢性炎症性皮肤病，不仅影响外观，还可能给患者的心理带来重大负担。而癌症则是我们现代人最大的健康威胁之一。最近，诺华制药 (NVS.US)因其银屑病药物Cosentyx和癌症药物Kisqali等的销售强劲，再次上调了年度利润指引。这一消息不仅引发了投资者的关注，也为广大患者带来了新的希望。

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.